Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:IFRX NASDAQ:INMB NASDAQ:KRON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$2.75-1.4%$2.86$2.00▼$5.00$11.52M2.1393,224 shs95,366 shsIFRXInflaRx$0.87+1.8%$1.08$0.71▼$2.82$58.07M1.29306,996 shs161,739 shsINMBINmune Bio$2.25-4.1%$6.02$1.89▼$11.64$52.94M1.34839,396 shs865,697 shsKRONKronos Bio$0.88+1.5%$0.80$0.65▼$1.51$53.72M1.64366,193 shs54,089 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos-2.45%-12.54%+10.80%+1.45%-25.45%IFRXInflaRx+4.42%-4.93%+8.97%-19.81%-49.40%INMBINmune Bio+13.04%-0.85%-70.82%-68.03%-76.27%KRONKronos Bio0.00%0.00%-0.85%-0.90%-41.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos1.5431 of 5 stars0.05.00.00.02.51.70.6IFRXInflaRx2.7507 of 5 stars3.53.00.00.02.61.70.6INMBINmune Bio2.3196 of 5 stars3.31.00.00.03.81.70.6KRONKronos BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/AIFRXInflaRx 3.00Buy$6.60663.01% UpsideINMBINmune Bio 2.57Moderate Buy$18.40719.60% UpsideKRONKronos Bio 2.33Hold$1.6384.66% UpsideCurrent Analyst Ratings BreakdownLatest AIMD, IFRX, INMB, and KRON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025INMBINmune BioMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $8.007/1/2025INMBINmune BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral7/1/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Underperform6/30/2025INMBINmune BioRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold5/29/2025IFRXInflaRxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$2.005/29/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$6.00 ➝ $3.005/8/2025IFRXInflaRxOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.004/29/2025IFRXInflaRxCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$10.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$20K576.13N/AN/A$5.51 per share0.50IFRXInflaRx$180K322.60N/AN/A$1.13 per share0.77INMBINmune Bio$10K5,293.71N/AN/A$1.45 per share1.55KRONKronos Bio$9.85M5.45N/AN/A$1.45 per share0.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.86M-$6.45N/A∞N/AN/A-88.07%-48.60%8/4/2025 (Estimated)IFRXInflaRx-$49.85M-$0.82N/AN/AN/AN/A-64.17%-53.39%8/6/2025 (Estimated)INMBINmune Bio-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)KRONKronos Bio-$86.08M-$1.07N/AN/AN/A-701.53%-64.22%-47.17%8/6/2025 (Estimated)Latest AIMD, IFRX, INMB, and KRON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IFRXInflaRx-$0.24N/AN/AN/AN/AN/A8/7/2025Q2 2025INMBINmune Bio-$0.37N/AN/AN/AN/AN/A5/12/2025Q1 2025AIMDAinosN/A-$1.05N/A-$0.21N/A$0.11 million5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 million5/7/2025Q1 2025IFRXInflaRx-$0.18-$0.14+$0.04-$0.14$0.03 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AKRONKronos BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.842.001.91IFRXInflaRxN/A5.284.86INMBINmune BioN/A2.642.64KRONKronos BioN/A12.9312.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/AIFRXInflaRx42.39%INMBINmune Bio12.72%KRONKronos Bio64.09%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%IFRXInflaRx16.30%INMBINmune Bio35.70%KRONKronos Bio24.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos404.19 million3.76 millionNot OptionableIFRXInflaRx6067.13 million56.19 millionOptionableINMBINmune Bio1023.58 million15.17 millionOptionableKRONKronos Bio10061.05 million46.16 millionOptionableAIMD, IFRX, INMB, and KRON HeadlinesRecent News About These Companies$1.8 billion fund is gobbling up Bay Area biotech 'zombies' for cheapJuly 9, 2025 | msn.comKronos Bio (NASDAQ:KRON) Rating Increased to Hold at Wall Street ZenJune 21, 2025 | marketbeat.comKronos Bio Completes Merger with Concentra BiosciencesJune 20, 2025 | tipranks.comKronos Bio, Inc. (NASDAQ:KRON) Short Interest UpdateJune 17, 2025 | marketbeat.comInsider Selling: Kronos Bio, Inc. (NASDAQ:KRON) CEO Sells 24,838 Shares of StockJune 7, 2025 | insidertrades.comKronos Bio sends Cambridge lab space back to marketJune 5, 2025 | bizjournals.comKronos Bio Terminates Cambridge Lease AgreementJune 5, 2025 | tipranks.comOrca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial OfficerJune 4, 2025 | finance.yahoo.comKronos Bio, Board Sued by Shareholder Over Concentra Buyout DealMay 21, 2025 | news.bloomberglaw.comNConcentra Biosciences Agrees to Acquire Kronos BioMay 5, 2025 | contractpharma.comCKRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRONMay 4, 2025 | businesswire.comConcentra To Acquire Kronos BioMay 3, 2025 | nasdaq.comConcentra acquires struggling small-molecule biotech KronosMay 2, 2025 | fiercebiotech.comFKronos shares slump on Concentra takeover newsMay 2, 2025 | thepharmaletter.comTSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc. - KRONMay 1, 2025 | prnewswire.comAfter hunt for alternatives, Kronos Bio selects Tang Capital's Concentra for a dealMay 1, 2025 | endpts.comEKronos Bio Agrees to Be Acquired by Concentra BiosciencesMay 1, 2025 | marketwatch.comShareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public ShareholdersMay 1, 2025 | businesswire.comKRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to ShareholdersMay 1, 2025 | businesswire.comKronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value RightMay 1, 2025 | finance.yahoo.comKronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value RightMay 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIMD, IFRX, INMB, and KRON Company DescriptionsAinos NASDAQ:AIMD$2.75 -0.04 (-1.43%) As of 02:38 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.InflaRx NASDAQ:IFRX$0.86 +0.02 (+1.76%) As of 02:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.INmune Bio NASDAQ:INMB$2.24 -0.10 (-4.06%) As of 03:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Kronos Bio NASDAQ:KRON$0.88 +0.01 (+1.49%) As of 06/20/2025 This is a fair market value price provided by Polygon.io. Learn more.Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
